Risk Factors for the Discontinuation of Liraglutide Due to Adverse Events

DOI Web Site
  • Itai Shingo
    Department of Hospital Pharmacy, University Hospital, Kanazawa University
  • Suga Yukio
    Faculty of Pharmacy, Institute of Medical, Pharmaceutical & Health Science, Kanazawa University
  • Osada Sachie
    Department of Hospital Pharmacy, University Hospital, Kanazawa University
  • Kawamura Saki
    Department of Hospital Pharmacy, University Hospital, Kanazawa University
  • Shimura Mao
    Department of Hospital Pharmacy, University Hospital, Kanazawa University
  • Aburaya Megumi
    Department of Hospital Pharmacy, University Hospital, Kanazawa University
  • Shimura Yusuke
    Department of Hospital Pharmacy, University Hospital, Kanazawa University
  • Motoya Wakako
    Department of Hospital Pharmacy, University Hospital, Kanazawa University
  • Higuchi Maiko
    Department of Hospital Pharmacy, University Hospital, Kanazawa University
  • Date Junichirou
    Department of Hospital Pharmacy, University Hospital, Kanazawa University
  • Kawano Mio
    Department of Hospital Pharmacy, University Hospital, Kanazawa University
  • Yagi Kunimasa
    Department of Endocrinology and Metabolism, Kanazawa University
  • Takamura Toshinari
    Department of Endocrinology and Metabolism, Kanazawa University
  • Sai Yoshimichi
    Department of Hospital Pharmacy, University Hospital, Kanazawa University
  • Takeda Jinyu
    Department of Endocrinology and Metabolism, Kanazawa University
  • Miyamoto Ken-ichi
    Department of Hospital Pharmacy, University Hospital, Kanazawa University

Bibliographic Information

Other Title
  • リラグルチドの有害事象による中止の危険因子の探索
  • 診断・治療(食事・運動・薬物) リラグルチドの有害事象による中止の危険因子の探索
  • シンダン ・ チリョウ(ショクジ ・ ウンドウ ・ ヤクブツ) リラグルチド ノ ユウガイ ジショウ ニ ヨル チュウシ ノ キケン インシ ノ タンサク

Search this article

Abstract

Liraglutide is occasionally discontinued due to the onset of adverse events, such as gastrointestinal disorders. We retrospectively investigated risk factors for the discontinuation of liraglutide in patients treated at Kanazawa University Hospital. Independent risk factors for the discontinuation of liraglutide were identified according to a multivariate logistic regression analysis. The incidence of adverse events was 67.2 % in the patients treated with liraglutide, and the discontinuation rate was 11.5 %. Risk factors for the discontinuation of liraglutide included severe renal impairment (estimated glomerular filtration rate<30 ml/min/1.73 m2 or treatment with hemodialysis) and chronic diabetes mellitus (≥15 years). These data suggest that it is necessary to determine the characteristics of patients with type 2 diabetes mellitus before administering liraglutide and that the dose of liraglutide should be increased carefully in patients with risk factors.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top